urovestВестник урологииUrology Herald2308-6424Rostov State Medical University10.21886/2308-6424-2026-14-1-93-105urovest-1191Research ArticleОБЗОРЫ ЛИТЕРАТУРЫREVIEWS ARTICLEЭффективность и безопасность антибиотикотерапии и антибиотикопрофилактики инфекций мочевыводящих путей при пузырно-мочеточниковом рефлюксе у детейEfficacy and safety of antibiotic therapy and prophylaxis of urinary tract infections in children with vesicoureteral refluxhttps://orcid.org/0000-0002-4808-7024НабокаЮ. Л.NabokaYu. L.

Юлия Лазаревна Набока — д-р мед. наук, профессор

Ростов-на-Дону

Yulia L. Naboka — Dr.Sc.(Med), Full Prof.

Rostov-on-Don

nagu22@mail.ruhttps://orcid.org/0000-0002-5595-8799КотиеваЕ. М.KotievaE. M.

Елизавета Михайловна Котиева

Ростов-на-Дону

Elizaveta M. Kotieva

Rostov-on-Don

elizaveta.kotieva@mail.ruhttps://orcid.org/0000-0001-9145-8671СизоновВ. В.SizonovV. V.

Владимир Валентинович Сизонов — д-р мед. наук, профессор

Ростов-на-Дону

Vladimir V. Sizonov — Dr.Sc.(Med.); Full Prof.

Rostov-on-Don

vsizonov@mail.ruhttps://orcid.org/0009-0004-7701-5064РодинаР. А.RodinaR. A.

Роза Алексеевна Родина

Ростов-на-Дону

Roza A. Rodina

Rostov-on-Don

rozarodina0208@yandex.ruhttps://orcid.org/0000-0002-1710-0169КоганМ. И.KoganM. I.

Михаил Иосифович Коган — д-р мед. наук, профессор, заслуженный деятель науки РФ

Ростов-на-Дону, Россия

Mikhail I. Kogan — Dr.Sc.(Med), Full Prof., Hons. Sci. of the Russian Federation

Rostov-on-Don

dept_kogan@mail.ruРостовский государственный медицинский университетРоссияRostov State Medical UniversityRussian FederationРостовский государственный медицинский университет; Областная детская клиническая больница»РоссияRostov State Medical University; Rostov Regional Children's Clinical HospitalRussian Federation20260504202614193105Copyright © Набока Ю.Л., Котиева Е.М., Сизонов В.В., Родина Р.А., Коган М.И., 20262026Набока Ю.Л., Котиева Е.М., Сизонов В.В., Родина Р.А., Коган М.И.Naboka Y.L., Kotieva E.M., Sizonov V.V., Rodina R.A., Kogan M.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.urovest.ru/jour/article/view/1191

Пузырно-мочеточниковый рефлюкс (ПМР) — актуальная проблема в педиатрической урологии, поскольку он увеличивает риск развития инфекции мочевыводящих путей (ИМП), что может в свою очередь привести к повреждению почек и развитию хронической почечной недостаточности у детей. Зачастую отправной точкой к постановке диагноза «ПМР» служит дебют ИМП. Антибиотикотерапия является основным методом лечения ИМП, а антибиотикопрофилактика используется для предупреждения её рецидивов и инфекционных осложнений у детей, находящихся на лечении ПМР. Однако длительное применение антибиотиков сопряжено со значительными рисками, в том числе вероятностью развития антибиотикорезистентности. В данной обзорной статье рассматриваются эффективность и безопасность существующего на сегодняшний день терапевтического подхода к медикаментозной терапии и профилактике у детей с ПМР. Особое внимание уделяется оптимизации методов ведения таких пациентов, а также современным рекомендациям, направленным на минимизацию рецидивов и улучшение клинических исходов.

Vesicoureteral reflux (VUR) is a common condition in paediatric urology that increases the risk of urinary tract infection (UTI), which in turn may result in renal scarring and the development of chronic kidney disease in children. A first episode of UTI is often the trigger for the diagnosis of VUR. Antibiotic therapy remains the mainstay of UTI management, while continuous antibiotic prophylaxis is used to prevent recurrence and infectious complications in children with VUR. However, prolonged antibiotic use is associated with important risks, including the development of antimicrobial resistance. This review evaluates the efficacy and safety of contemporary antibiotic treatment and prophylactic strategies in children with VUR. Particular emphasis is placed on optimizing patient management and on current guideline-based recommendations aimed at reducing recurrence rates and improving clinical outcomes.

пузырно-мочеточниковый рефлюксинфекции мочевыводящих путеймедикаментозная терапиямикробиологиядетиvesico-ureteral refluxurinary tract infectionsdrug therapymicrobiologychildrenИсследование не имело спонсорской поддержки.The study was not sponsored.ReferencesMattoo TK, Shaikh N, Nelson CP. Contemporary Management of Urinary Tract Infection in Children. Pediatrics. 2021;147(2):e2020012138. Erratum in: Pediatrics. 2022;150(4):e2022059259. DOI: 10.1542/peds.2020-012138Mattoo TK, Shaikh N, Nelson CP. Contemporary Management of Urinary Tract Infection in Children. Pediatrics. 2021;147(2):e2020012138. Erratum in: Pediatrics. 2022;150(4):e2022059259. DOI: 10.1542/peds.2020-012138Miyakita H, Hayashi Y, Mitsui T, Okawada M, Kinoshita Y, Kimata T, Koikawa Y, Sakai K, Satoh H, Tokunaga M, Naitoh Y, Niimura F, Matsuoka H, Mizuno K, Kaneko K, Kubota M. Guidelines for the medical management of pediatric vesicoureteral reflux. Int J Urol. 2020;27(6):480-490. DOI: 10.1111/iju.14223Miyakita H, Hayashi Y, Mitsui T, Okawada M, Kinoshita Y, Kimata T, Koikawa Y, Sakai K, Satoh H, Tokunaga M, Naitoh Y, Niimura F, Matsuoka H, Mizuno K, Kaneko K, Kubota M. Guidelines for the medical management of pediatric vesicoureteral reflux. Int J Urol. 2020;27(6):480-490. DOI: 10.1111/iju.14223Thergaonkar RW, Hari P. Current Management of Urinary Tract Infection and Vesicoureteral Reflux. Indian J Pediatr. 2020;87(8):625-632. DOI: 10.1007/s12098-019-03099-9Thergaonkar RW, Hari P. Current Management of Urinary Tract Infection and Vesicoureteral Reflux. Indian J Pediatr. 2020;87(8):625-632. DOI: 10.1007/s12098-019-03099-9Olson P, Dudley AG, Rowe CK. Contemporary Management of Urinary Tract Infections in Children. Curr Treat Options Pediatr. 2022;8(3):192- 210. DOI: 10.1007/s40746-022-00242-1Olson P, Dudley AG, Rowe CK. Contemporary Management of Urinary Tract Infections in Children. Curr Treat Options Pediatr. 2022;8(3):192- 210. DOI: 10.1007/s40746-022-00242-1‘t Hoen LA, Bogaert G, Radmayr C, Dogan HS, Nijman RJM, QuaedackersJ, Rawashdeh YF, Silay MS, Tekgul S, Bhatt NR, Stein R. Update of the EAU/ESPU guidelines on urinary tract infections in children. J Pediatr Urol. 2021;17(2):200-207. Erratum in: J Pediatr Urol. 2021;17(4):598. DOI: 10.1016/j.jpurol.2021.01.037‘t Hoen LA, Bogaert G, Radmayr C, Dogan HS, Nijman RJM, QuaedackersJ, Rawashdeh YF, Silay MS, Tekgul S, Bhatt NR, Stein R. Update of the EAU/ESPU guidelines on urinary tract infections in children. J Pediatr Urol. 2021;17(2):200-207. Erratum in: J Pediatr Urol. 2021;17(4):598. DOI: 10.1016/j.jpurol.2021.01.037EAU Guidelines. Edn. presented at the EAU Annual Congress Paris 2024. ISBN 978-94-92671-23-3. Accessed on June 20, 2025 URL: https://uroweb.org/guidelinesEAU Guidelines. Edn. presented at the EAU Annual Congress Paris 2024. ISBN 978-94-92671-23-3. Accessed on June 20, 2025 URL: https://uroweb.org/guidelinesHewitt IK, Roebuck DJ, Montini G. Conflicting views of physicians and surgeons concerning pediatric urinary tract infection: a comparative review. Pediatr Radiol. 2023;53(13):2651-2661. DOI: 10.1007/s00247-023-05771-xHewitt IK, Roebuck DJ, Montini G. Conflicting views of physicians and surgeons concerning pediatric urinary tract infection: a comparative review. Pediatr Radiol. 2023;53(13):2651-2661. DOI: 10.1007/s00247-023-05771-xPage MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hróbjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. DOI: 10.1136/bmj.n71Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hróbjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. DOI: 10.1136/bmj.n71Läckgren G, Cooper CS, Neveus T, Kirsch AJ. Management of Vesicoureteral Reflux: What Have We Learned Over the Last 20 Years? Front Pediatr. 2021;9:650326. DOI: 10.3389/fped.2021.650326Läckgren G, Cooper CS, Neveus T, Kirsch AJ. Management of Vesicoureteral Reflux: What Have We Learned Over the Last 20 Years? Front Pediatr. 2021;9:650326. DOI: 10.3389/fped.2021.650326Chirico V, Tripodi F, Lacquaniti A, Monardo P, Conti G, Ascenti G, Chimenz R. Therapeutic Management of Children with Vesicoureteral Reflux. J Clin Med. 2023;13(1):244. DOI: 10.3390/jcm13010244Chirico V, Tripodi F, Lacquaniti A, Monardo P, Conti G, Ascenti G, Chimenz R. Therapeutic Management of Children with Vesicoureteral Reflux. J Clin Med. 2023;13(1):244. DOI: 10.3390/jcm13010244Schwab CW Jr, Wu HY, Selman H, Smith GH, Snyder HM 3rd, Canning DA. Spontaneous resolution of vesicoureteral reflux: a 15-year perspective. J Urol. 2002;168(6):2594-2599. DOI: 10.1016/S0022-5347(05)64225-5Schwab CW Jr, Wu HY, Selman H, Smith GH, Snyder HM 3rd, Canning DA. Spontaneous resolution of vesicoureteral reflux: a 15-year perspective. J Urol. 2002;168(6):2594-2599. DOI: 10.1016/S0022-5347(05)64225-5Meena J, Mathew G, Hari P, Sinha A, Bagga A. Prevalence of Bladder and Bowel Dysfunction in Toilet-Trained Children With Urinary Tract Infection and/or Primary Vesicoureteral Reflux: A Systematic Review and Meta-Analysis. Front Pediatr. 2020;8:84. DOI: 10.3389/fped.2020.00084Meena J, Mathew G, Hari P, Sinha A, Bagga A. Prevalence of Bladder and Bowel Dysfunction in Toilet-Trained Children With Urinary Tract Infection and/or Primary Vesicoureteral Reflux: A Systematic Review and Meta-Analysis. Front Pediatr. 2020;8:84. DOI: 10.3389/fped.2020.00084Gnech M, ‘t Hoen L, Zachou A, Bogaert G, Castagnetti M, O’Kelly F, Quaedackers J, Rawashdeh YF, Silay MS, Kennedy U, Skott M, van Uitert A, Yuan Y, Radmayr C, Burgu B. Update and Summary of the European Association of Urology/European Society of Paediatric Urol ogy Paediatric Guidelines on Vesicoureteral Reflux in Children. Eur Urol. 2024;85(5):433-442. DOI: 10.1016/j.eururo.2023.12.005Gnech M, ‘t Hoen L, Zachou A, Bogaert G, Castagnetti M, O’Kelly F, Quaedackers J, Rawashdeh YF, Silay MS, Kennedy U, Skott M, van Uitert A, Yuan Y, Radmayr C, Burgu B. Update and Summary of the European Association of Urology/European Society of Paediatric Urol ogy Paediatric Guidelines on Vesicoureteral Reflux in Children. Eur Urol. 2024;85(5):433-442. DOI: 10.1016/j.eururo.2023.12.005Pensabene M, Cimador M, Spataro B, Serra G, Baldanza F, Grasso F, Corsello G, Salerno S, Di Pace MR, Sergio M. Intraoperative ultrasoundassisted endoscopic treatment of primary intermediate and high-grade vesicoureteral reflux in children in a long-term follow-up. J Pediatr Urol. 2024;20(1):132.e1-132.e11. DOI: 10.1016/j.jpurol.2023.10.008Pensabene M, Cimador M, Spataro B, Serra G, Baldanza F, Grasso F, Corsello G, Salerno S, Di Pace MR, Sergio M. Intraoperative ultrasoundassisted endoscopic treatment of primary intermediate and high-grade vesicoureteral reflux in children in a long-term follow-up. J Pediatr Urol. 2024;20(1):132.e1-132.e11. DOI: 10.1016/j.jpurol.2023.10.008SUBCOMMITTEE ON URINARY TRACT INFECTION. Reaffirmation of AAP Clinical Practice Guideline: The Diagnosis and Management of the Initial Urinary Tract Infection in Febrile Infants and Young Children 2-24 Months of Age. Pediatrics. 2016;138(6):e20163026. DOI: 10.1542/peds.2016-3026SUBCOMMITTEE ON URINARY TRACT INFECTION. Reaffirmation of AAP Clinical Practice Guideline: The Diagnosis and Management of the Initial Urinary Tract Infection in Febrile Infants and Young Children 2-24 Months of Age. Pediatrics. 2016;138(6):e20163026. DOI: 10.1542/peds.2016-3026Alberici I, Bayazit AK, Drozdz D, Emre S, Fischbach M, Harambat J, Jankauskiene A, Litwin M, Mir S, Morello W, Peco-Antic A, Sallay P, Sever L, Simonetti GD, Szczesniak P, Teixeira A, Vidal E, Wuehl E, Mehls O, Weber LT, Schaefer F, Montini G; ESCAPE Study Group; PREDICT Trial. Pathogens causing urinary tract infections in infants: a European overview by the ESCAPE study group. Eur J Pediatr. 2015;174(6):783-790. DOI: 10.1007/s00431-014-2459-3Alberici I, Bayazit AK, Drozdz D, Emre S, Fischbach M, Harambat J, Jankauskiene A, Litwin M, Mir S, Morello W, Peco-Antic A, Sallay P, Sever L, Simonetti GD, Szczesniak P, Teixeira A, Vidal E, Wuehl E, Mehls O, Weber LT, Schaefer F, Montini G; ESCAPE Study Group; PREDICT Trial. Pathogens causing urinary tract infections in infants: a European overview by the ESCAPE study group. Eur J Pediatr. 2015;174(6):783-790. DOI: 10.1007/s00431-014-2459-3Morello W, D’Amico F, Serafinelli J, Turroni S, Abati I, Fiori J, Baskin E, Yalcinkaya F, Jankauskiene A, Pennesi M, Zurowska A, Becherucci F, Drozdz D, Mekahli D, Krzemien G, La Scola C, Taranta-Janusz K, Mehls O, Schaefer F, Candela M, Montini G. Low-Dose Antibiotic Prophylaxis Induces Rapid Modifications of the Gut Microbiota in Infants With Vesicoureteral Reflux. Front Pediatr. 2021;9:674716. DOI: 10.3389/fped.2021.674716Morello W, D’Amico F, Serafinelli J, Turroni S, Abati I, Fiori J, Baskin E, Yalcinkaya F, Jankauskiene A, Pennesi M, Zurowska A, Becherucci F, Drozdz D, Mekahli D, Krzemien G, La Scola C, Taranta-Janusz K, Mehls O, Schaefer F, Candela M, Montini G. Low-Dose Antibiotic Prophylaxis Induces Rapid Modifications of the Gut Microbiota in Infants With Vesicoureteral Reflux. Front Pediatr. 2021;9:674716. DOI: 10.3389/fped.2021.674716Yang Z, Dai K, Sun X, Tian C, Yuan L, Liu J, Li B, Chung PHY, Wong KKY. Comparison and clinical analysis of antibiotics and endoscopic injection for vesicoureteral reflux in children. Pediatr Surg Int. 2024;40(1):184. DOI: 10.1007/s00383-024-05780-3Yang Z, Dai K, Sun X, Tian C, Yuan L, Liu J, Li B, Chung PHY, Wong KKY. Comparison and clinical analysis of antibiotics and endoscopic injection for vesicoureteral reflux in children. Pediatr Surg Int. 2024;40(1):184. DOI: 10.1007/s00383-024-05780-3Garcia-Roig ML, Kirsch AJ. Urinary tract infection in the setting of vesicoureteral reflux. F1000Res. 2016;5:F1000 Faculty Rev-1552. DOI: 10.12688/f1000research.8390.1Garcia-Roig ML, Kirsch AJ. Urinary tract infection in the setting of vesicoureteral reflux. F1000Res. 2016;5:F1000 Faculty Rev-1552. DOI: 10.12688/f1000research.8390.1Pohl HG, de Winter JP, Milani GP. Vesicoureteral reflux: we have yet to complete our learning. Eur J Pediatr. 2021;180(5):1381-1382. DOI: 10.1007/s00431-021-03972-wPohl HG, de Winter JP, Milani GP. Vesicoureteral reflux: we have yet to complete our learning. Eur J Pediatr. 2021;180(5):1381-1382. DOI: 10.1007/s00431-021-03972-wChang CL, Yang SS, Hsu CK, Chen CH, Chang SJ. Effectiveness of various treatment modalities in children with vesicoureteral reflux grades II-IV: a systematic review and network meta-analysis. BMJ Paediatr Open. 2023;7(1):e002096. DOI: 10.1136/bmjpo-2023-002096Chang CL, Yang SS, Hsu CK, Chen CH, Chang SJ. Effectiveness of various treatment modalities in children with vesicoureteral reflux grades II-IV: a systematic review and network meta-analysis. BMJ Paediatr Open. 2023;7(1):e002096. DOI: 10.1136/bmjpo-2023-002096Holmdahl G, Brandström P, Läckgren G, Sillén U, Stokland E, Jodal U, Hansson S. The Swedish reflux trial in children: II. Vesicoureteral reflux outcome. J Urol. 2010;184(1):280-285. DOI: 10.1016/j.juro.2010.01.059Holmdahl G, Brandström P, Läckgren G, Sillén U, Stokland E, Jodal U, Hansson S. The Swedish reflux trial in children: II. Vesicoureteral reflux outcome. J Urol. 2010;184(1):280-285. DOI: 10.1016/j.juro.2010.01.059Keren R, Carpenter MA, Hoberman A, Shaikh N, Matoo TK, Chesney RW, Matthews R, Gerson AC, Greenfield SP, Fivush B, McLurie GA, Rushton HG, Canning D, Nelson CP, Greenbaum L, Bukowski T, Primack W, Sutherland R, Hosking J, Stewart D, Elder J, Moxey-Mims M, Nyberg L. Rationale and design issues of the Randomized Intervention for Children With Vesicoureteral Reflux (RIVUR) study. Pediatrics. 2008;122 Suppl 5(Suppl 5):S240-50. DOI: 10.1542/peds.2008-1285dKeren R, Carpenter MA, Hoberman A, Shaikh N, Matoo TK, Chesney RW, Matthews R, Gerson AC, Greenfield SP, Fivush B, McLurie GA, Rushton HG, Canning D, Nelson CP, Greenbaum L, Bukowski T, Primack W, Sutherland R, Hosking J, Stewart D, Elder J, Moxey-Mims M, Nyberg L. Rationale and design issues of the Randomized Intervention for Children With Vesicoureteral Reflux (RIVUR) study. Pediatrics. 2008;122 Suppl 5(Suppl 5):S240-50. DOI: 10.1542/peds.2008-1285dCraig JC, Simpson JM, Williams GJ, Lowe A, Reynolds GJ, McTaggart SJ, Hodson EM, Carapetis JR, Cranswick NE, Smith G, Irwig LM, Caldwell PH, Hamilton S, Roy LP; Prevention of Recurrent Urinary Tract Infection in Children with Vesicoureteric Reflux and Normal Renal Tracts (PRIVENT) Investigators. Antibiotic prophylaxis and recurrent urinary tract infection in children. N Engl J Med. 2009;361(18):1748-1759. Erratum in: N Engl J Med. 2010;362(13):1250. DOI: 10.1056/NEJMoa0902295Craig JC, Simpson JM, Williams GJ, Lowe A, Reynolds GJ, McTaggart SJ, Hodson EM, Carapetis JR, Cranswick NE, Smith G, Irwig LM, Caldwell PH, Hamilton S, Roy LP; Prevention of Recurrent Urinary Tract Infection in Children with Vesicoureteric Reflux and Normal Renal Tracts (PRIVENT) Investigators. Antibiotic prophylaxis and recurrent urinary tract infection in children. N Engl J Med. 2009;361(18):1748-1759. Erratum in: N Engl J Med. 2010;362(13):1250. DOI: 10.1056/NEJMoa0902295Carpenter MA, Hoberman A, Mattoo TK, Mathews R, Keren R, Chesney RW, Moxey-Mims M, Greenfield SP; RIVUR Trial Investigators. The RIVUR trial: profile and baseline clinical associations of children with vesicoureteral reflux. Pediatrics. 2013;132(1):e34-45. DOI: 10.1542/peds.2012-2301Carpenter MA, Hoberman A, Mattoo TK, Mathews R, Keren R, Chesney RW, Moxey-Mims M, Greenfield SP; RIVUR Trial Investigators. The RIVUR trial: profile and baseline clinical associations of children with vesicoureteral reflux. Pediatrics. 2013;132(1):e34-45. DOI: 10.1542/peds.2012-2301Zhao B, Ivanova A, Shaikh N. Antimicrobial prophylaxis for vesicoureteral reflux: which subgroups of children benefit the most? Pediatr Nephrol. 2024;39(6):1859-1863. DOI: 10.1007/s00467-024-06291-yZhao B, Ivanova A, Shaikh N. Antimicrobial prophylaxis for vesicoureteral reflux: which subgroups of children benefit the most? Pediatr Nephrol. 2024;39(6):1859-1863. DOI: 10.1007/s00467-024-06291-yShaikh N, Rajakumar V, Peterson CG, Gorski J, Ivanova A, Gravens Muller L, Miyashita Y, Smith KJ, Mattoo T, Pohl HG, Mathews R, Greenfield SP, Docimo SG, Hoberman A. Cost-Utility of Antimicrobial Prophylaxis for Treatment of Children With Vesicoureteral Reflux. Front Pediatr. 2020;7:530. DOI: 10.3389/fped.2019.00530Shaikh N, Rajakumar V, Peterson CG, Gorski J, Ivanova A, Gravens Muller L, Miyashita Y, Smith KJ, Mattoo T, Pohl HG, Mathews R, Greenfield SP, Docimo SG, Hoberman A. Cost-Utility of Antimicrobial Prophylaxis for Treatment of Children With Vesicoureteral Reflux. Front Pediatr. 2020;7:530. DOI: 10.3389/fped.2019.00530Copp HL, Nelson CP, Shortliffe LD, Lai J, Saigal CS, Kennedy WA; Urologic Diseases in America Project. Compliance with antibiotic prophylaxis in children with vesicoureteral reflux: results from a national pharmacy claims database. J Urol. 2010;183(5):1994-1999. DOI: 10.1016/j.juro.2010.01.036Copp HL, Nelson CP, Shortliffe LD, Lai J, Saigal CS, Kennedy WA; Urologic Diseases in America Project. Compliance with antibiotic prophylaxis in children with vesicoureteral reflux: results from a national pharmacy claims database. J Urol. 2010;183(5):1994-1999. DOI: 10.1016/j.juro.2010.01.036Pennesi M, Travan L, Peratoner L, Bordugo A, Cattaneo A, Ronfani L, Minisini S, Ventura A; North East Italy Prophylaxis in VUR study group. Is antibiotic prophylaxis in children with vesicoureteral reflux effective in preventing pyelonephritis and renal scars? A randomized, controlled trial. Pediatrics. 2008;121(6):e1489-1494. DOI: 10.1542/peds.2007-2652Pennesi M, Travan L, Peratoner L, Bordugo A, Cattaneo A, Ronfani L, Minisini S, Ventura A; North East Italy Prophylaxis in VUR study group. Is antibiotic prophylaxis in children with vesicoureteral reflux effective in preventing pyelonephritis and renal scars? A randomized, controlled trial. Pediatrics. 2008;121(6):e1489-1494. DOI: 10.1542/peds.2007-2652Garin EH, Olavarria F, Garcia Nieto V, Valenciano B, Campos A, Young L. Clinical significance of primary vesicoureteral reflux and urinary antibiotic prophylaxis after acute pyelonephritis: a multicenter, randomized, controlled study. Pediatrics. 2006;117(3):626-632. DOI: 10.1542/peds.2005-1362Garin EH, Olavarria F, Garcia Nieto V, Valenciano B, Campos A, Young L. Clinical significance of primary vesicoureteral reflux and urinary antibiotic prophylaxis after acute pyelonephritis: a multicenter, randomized, controlled study. Pediatrics. 2006;117(3):626-632. DOI: 10.1542/peds.2005-1362Hari P, Hari S, Sinha A, Kumar R, Kapil A, Pandey RM, Bagga A. Antibiotic prophylaxis in the management of vesicoureteric reflux: a randomized double-blind placebo-controlled trial. Pediatr Nephrol. 2015;30(3):479- 486. DOI: 10.1007/s00467-014-2943-zHari P, Hari S, Sinha A, Kumar R, Kapil A, Pandey RM, Bagga A. Antibiotic prophylaxis in the management of vesicoureteric reflux: a randomized double-blind placebo-controlled trial. Pediatr Nephrol. 2015;30(3):479- 486. DOI: 10.1007/s00467-014-2943-zMorello W, Baskin E, Jankauskiene A, Yalcinkaya F, Zurowska A, Puccio G, Serafinelli J, La Manna A, Krzemień G, Pennesi M, La Scola C, Becherucci F, Brugnara M, Yuksel S, Mekahli D, Chimenz R, De Palma D, Zucchetta P, Vajauskas D, Drozdz D, Szczepanska M, Caliskan S, Lombet J, Minoli DG, Guarino S, Gulleroglu K, Ruzgiene D, Szmigielska A, Barbi E, Ozcakar ZB, Kranz A, Pasini A, Materassi M, De Rechter S, Ariceta G, Weber LT, Marzuillo P, Alberici I, Taranta-Janusz K, Caldas Afonso A, Tkaczyk M, Català M, Cabrera Sevilla JE, Mehls O, Schaefer F, Montini G; PREDICT Study Group. Antibiotic Prophylaxis in Infants with Grade III, IV, or V Vesicoureteral Reflux. N Engl J Med. 2023;389(11):987-997. DOI: 10.1056/NEJMoa2300161Morello W, Baskin E, Jankauskiene A, Yalcinkaya F, Zurowska A, Puccio G, Serafinelli J, La Manna A, Krzemień G, Pennesi M, La Scola C, Becherucci F, Brugnara M, Yuksel S, Mekahli D, Chimenz R, De Palma D, Zucchetta P, Vajauskas D, Drozdz D, Szczepanska M, Caliskan S, Lombet J, Minoli DG, Guarino S, Gulleroglu K, Ruzgiene D, Szmigielska A, Barbi E, Ozcakar ZB, Kranz A, Pasini A, Materassi M, De Rechter S, Ariceta G, Weber LT, Marzuillo P, Alberici I, Taranta-Janusz K, Caldas Afonso A, Tkaczyk M, Català M, Cabrera Sevilla JE, Mehls O, Schaefer F, Montini G; PREDICT Study Group. Antibiotic Prophylaxis in Infants with Grade III, IV, or V Vesicoureteral Reflux. N Engl J Med. 2023;389(11):987-997. DOI: 10.1056/NEJMoa2300161Garin EH. Primary vesicoureteral reflux; what have we learnt from the recently published randomized, controlled trials? Pediatr Nephrol. 2019;34(9):1513-1519. DOI: 10.1007/s00467-018-4045-9Garin EH. Primary vesicoureteral reflux; what have we learnt from the recently published randomized, controlled trials? Pediatr Nephrol. 2019;34(9):1513-1519. DOI: 10.1007/s00467-018-4045-9Hewitt IK, Pennesi M, Morello W, Ronfani L, Montini G. Antibiotic Prophylaxis for Urinary Tract Infection-Related Renal Scarring: A Systematic Review. Pediatrics. 2017;139(5):e20163145. DOI: 10.1542/peds.2016-3145Hewitt IK, Pennesi M, Morello W, Ronfani L, Montini G. Antibiotic Prophylaxis for Urinary Tract Infection-Related Renal Scarring: A Systematic Review. Pediatrics. 2017;139(5):e20163145. DOI: 10.1542/peds.2016-3145Storm DW, Braga LH, Cooper CS. Continuous Antibiotic Prophylaxis in Pediatric Urology. Urol Clin North Am. 2018;45(4):525-538. DOI: 10.1016/j.ucl.2018.06.001Storm DW, Braga LH, Cooper CS. Continuous Antibiotic Prophylaxis in Pediatric Urology. Urol Clin North Am. 2018;45(4):525-538. DOI: 10.1016/j.ucl.2018.06.001Selekman RS, Shapiro DJ, Copp HL. Antimicrobial exposure and uropathogen resistance: an analysis of individual patient data from RCTs on antibiotic prophylaxis and prevention of UTI. American Urology Association Annual Meeting. New Orleans, LA, May 15-19, 2015.Selekman RS, Shapiro DJ, Copp HL. Antimicrobial exposure and uropathogen resistance: an analysis of individual patient data from RCTs on antibiotic prophylaxis and prevention of UTI. American Urology Association Annual Meeting. New Orleans, LA, May 15-19, 2015.Tasian G, Furth S. Narrowing the focus: what we now know (and still don’t know) about antibiotic prophylaxis for children with vesicoureteral reflux. Am J Kidney Dis. 2015;65(2):214-216. DOI: 10.1053/j.ajkd.2014.09.004Tasian G, Furth S. Narrowing the focus: what we now know (and still don’t know) about antibiotic prophylaxis for children with vesicoureteral reflux. Am J Kidney Dis. 2015;65(2):214-216. DOI: 10.1053/j.ajkd.2014.09.004Selekman RE, Shapiro DJ, Boscardin J, Williams G, Craig JC, Brandström P, Pennesi M, Roussey-Kesler G, Hari P, Copp HL. Uropathogen Resistance and Antibiotic Prophylaxis: A Meta-analysis. Pediatrics. 2018;142(1):e20180119. DOI: 10.1542/peds.2018-0119Selekman RE, Shapiro DJ, Boscardin J, Williams G, Craig JC, Brandström P, Pennesi M, Roussey-Kesler G, Hari P, Copp HL. Uropathogen Resistance and Antibiotic Prophylaxis: A Meta-analysis. Pediatrics. 2018;142(1):e20180119. DOI: 10.1542/peds.2018-0119Lee JN, Byeon KH, Woo MJ, Baek HS, Cho MH, Jeong SY, Lee SM, Ham JY, Ha YS, Kim HT, Yoo ES, Kwon TG, Chung SK. Susceptibility of the Index Urinary Tract Infection to Prophylactic Antibiotics Is a Predictive Factor of Breakthrough Urinary Tract Infection in Children with Primary Vesicoureteral Reflux Receiving Continuous Antibiotic Prophylaxis. J Korean Med Sci. 2019;34(21):e156. DOI: 10.3346/jkms.2019.34.e156Lee JN, Byeon KH, Woo MJ, Baek HS, Cho MH, Jeong SY, Lee SM, Ham JY, Ha YS, Kim HT, Yoo ES, Kwon TG, Chung SK. Susceptibility of the Index Urinary Tract Infection to Prophylactic Antibiotics Is a Predictive Factor of Breakthrough Urinary Tract Infection in Children with Primary Vesicoureteral Reflux Receiving Continuous Antibiotic Prophylaxis. J Korean Med Sci. 2019;34(21):e156. DOI: 10.3346/jkms.2019.34.e156Kurt-Şükür ED, Özçakar ZB, Doğan Ö, Öztürk M, Karaman M, Çakar N, Güriz H, Yalçınkaya F. The changing resistance patterns of bacterial uropathogens in children. Pediatr Int. 2020;62(9):1058-1063. DOI: 10.1111/ped.14270Kurt-Şükür ED, Özçakar ZB, Doğan Ö, Öztürk M, Karaman M, Çakar N, Güriz H, Yalçınkaya F. The changing resistance patterns of bacterial uropathogens in children. Pediatr Int. 2020;62(9):1058-1063. DOI: 10.1111/ped.14270Keeney KM, Yurist-Doutsch S, Arrieta MC, Finlay BB. Effects of antibiotics on human microbiota and subsequent disease. Annu Rev Microbiol. 2014;68:217-235. DOI: 10.1146/annurev-micro-091313-103456Keeney KM, Yurist-Doutsch S, Arrieta MC, Finlay BB. Effects of antibiotics on human microbiota and subsequent disease. Annu Rev Microbiol. 2014;68:217-235. DOI: 10.1146/annurev-micro-091313-103456Jakobsson HE, Jernberg C, Andersson AF, Sjölund-Karlsson M, Jansson JK, Engstrand L. Short-term antibiotic treatment has differing longterm impacts on the human throat and gut microbiome. PLoS One. 2010;5(3):e9836. DOI: 10.1371/journal.pone.0009836Jakobsson HE, Jernberg C, Andersson AF, Sjölund-Karlsson M, Jansson JK, Engstrand L. Short-term antibiotic treatment has differing longterm impacts on the human throat and gut microbiome. PLoS One. 2010;5(3):e9836. DOI: 10.1371/journal.pone.0009836Jernberg C, Löfmark S, Edlund C, Jansson JK. Long-term ecological impacts of antibiotic administration on the human intestinal microbiota. ISME J. 2007;1(1):56-66. Erratum in: ISME J. 2013;7(2):456. DOI: 10.1038/ismej.2007.3Jernberg C, Löfmark S, Edlund C, Jansson JK. Long-term ecological impacts of antibiotic administration on the human intestinal microbiota. ISME J. 2007;1(1):56-66. Erratum in: ISME J. 2013;7(2):456. DOI: 10.1038/ismej.2007.3Dethlefsen L, Relman DA. Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation. Proc Natl Acad Sci U S A. 2011;108 Suppl 1(Suppl 1):4554- 4561. DOI: 10.1073/pnas.1000087107Dethlefsen L, Relman DA. Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation. Proc Natl Acad Sci U S A. 2011;108 Suppl 1(Suppl 1):4554- 4561. DOI: 10.1073/pnas.1000087107Kelly CP, Pothoulakis C, LaMont JT. Clostridium difficile colitis. N Engl J Med. 1994;330(4):257-262. DOI: 10.1056/NEJM199401273300406Kelly CP, Pothoulakis C, LaMont JT. Clostridium difficile colitis. N Engl J Med. 1994;330(4):257-262. DOI: 10.1056/NEJM199401273300406Adler JL, Anderson RL, Boring JR 3rd, Nahmias AJ. A protracted hospitalassociated outbreak of salmonellosis due to a multiple-antibioticresistant strain of Salmonella indiana. J Pediatr. 1970;77(6):970-975. DOI: 10.1016/s0022-3476(70)80079-8Adler JL, Anderson RL, Boring JR 3rd, Nahmias AJ. A protracted hospitalassociated outbreak of salmonellosis due to a multiple-antibioticresistant strain of Salmonella indiana. J Pediatr. 1970;77(6):970-975. DOI: 10.1016/s0022-3476(70)80079-8Ajslev TA, Andersen CS, Gamborg M, Sørensen TI, Jess T. Childhood overweight after establishment of the gut microbiota: the role of delivery mode, pre-pregnancy weight and early administration of antibiotics. Int J Obes (Lond). 2011;35(4):522-529. DOI: 10.1038/ijo.2011.27Ajslev TA, Andersen CS, Gamborg M, Sørensen TI, Jess T. Childhood overweight after establishment of the gut microbiota: the role of delivery mode, pre-pregnancy weight and early administration of antibiotics. Int J Obes (Lond). 2011;35(4):522-529. DOI: 10.1038/ijo.2011.27Bailey LC, Forrest CB, Zhang P, Richards TM, Livshits A, DeRusso PA. Association of antibiotics in infancy with early childhood obesity. JAMA Pediatr. 2014;168(11):1063-1069. DOI: 10.1001/jamapediatrics.2014.1539 ,Bailey LC, Forrest CB, Zhang P, Richards TM, Livshits A, DeRusso PA. Association of antibiotics in infancy with early childhood obesity. JAMA Pediatr. 2014;168(11):1063-1069. DOI: 10.1001/jamapediatrics.2014.1539 ,Edmonson MB, Eickhoff JC. Weight Gain and Obesity in Infants and Young Children Exposed to Prolonged Antibiotic Prophylaxis. JAMA Pediatr. 2017;171(2):150-156. DOI: 10.1001/jamapediatrics.2016.3349Edmonson MB, Eickhoff JC. Weight Gain and Obesity in Infants and Young Children Exposed to Prolonged Antibiotic Prophylaxis. JAMA Pediatr. 2017;171(2):150-156. DOI: 10.1001/jamapediatrics.2016.3349Smith MI, Yatsunenko T, Manary MJ, Trehan I, Mkakosya R, Cheng J, Kau AL, Rich SS, Concannon P, Mychaleckyj JC, Liu J, Houpt E, Li JV, Holmes E, Nicholson J, Knights D, Ursell LK, Knight R, Gordon JI. Gut microbiomes of Malawian twin pairs discordant for kwashiorkor. Science. 2013;339(6119):548-554. DOI: 10.1126/science.1229000Smith MI, Yatsunenko T, Manary MJ, Trehan I, Mkakosya R, Cheng J, Kau AL, Rich SS, Concannon P, Mychaleckyj JC, Liu J, Houpt E, Li JV, Holmes E, Nicholson J, Knights D, Ursell LK, Knight R, Gordon JI. Gut microbiomes of Malawian twin pairs discordant for kwashiorkor. Science. 2013;339(6119):548-554. DOI: 10.1126/science.1229000Stefka AT, Feehley T, Tripathi P, Qiu J, McCoy K, Mazmanian SK, Tjota MY, Seo GY, Cao S, Theriault BR, Antonopoulos DA, Zhou L, Chang EB, Fu YX, Nagler CR. Commensal bacteria protect against food allergen sensitization. Proc Natl Acad Sci U S A. 2014;111(36):13145-13150. DOI: 10.1073/pnas.1412008111Stefka AT, Feehley T, Tripathi P, Qiu J, McCoy K, Mazmanian SK, Tjota MY, Seo GY, Cao S, Theriault BR, Antonopoulos DA, Zhou L, Chang EB, Fu YX, Nagler CR. Commensal bacteria protect against food allergen sensitization. Proc Natl Acad Sci U S A. 2014;111(36):13145-13150. DOI: 10.1073/pnas.1412008111Murk W, Risnes KR, Bracken MB. Prenatal or early-life exposure to antibiotics and risk of childhood asthma: a systematic review. Pediatrics. 2011;127(6):1125-1138. DOI: 10.1542/peds.2010-2092Murk W, Risnes KR, Bracken MB. Prenatal or early-life exposure to antibiotics and risk of childhood asthma: a systematic review. Pediatrics. 2011;127(6):1125-1138. DOI: 10.1542/peds.2010-2092Örtqvist AK, Lundholm C, Kieler H, Ludvigsson JF, Fall T, Ye W, Almqvist C. Antibiotics in fetal and early life and subsequent childhood asthma: nationwide population based study with sibling analysis. BMJ. 2014;349:g6979. Erratum in: BMJ. 2014;349:g7395. DOI: 10.1136/bmj.g6979Örtqvist AK, Lundholm C, Kieler H, Ludvigsson JF, Fall T, Ye W, Almqvist C. Antibiotics in fetal and early life and subsequent childhood asthma: nationwide population based study with sibling analysis. BMJ. 2014;349:g6979. Erratum in: BMJ. 2014;349:g7395. DOI: 10.1136/bmj.g6979Hviid A, Svanström H, Frisch M. Antibiotic use and inflammatory bowel diseases in childhood. Gut. 2011;60(1):49-54. DOI: 10.1136/gut.2010.219683Hviid A, Svanström H, Frisch M. Antibiotic use and inflammatory bowel diseases in childhood. Gut. 2011;60(1):49-54. DOI: 10.1136/gut.2010.219683Stapleton AE, Au-Yeung M, Hooton TM, Fredricks DN, Roberts PL, Czaja CA, Yarova-Yarovaya Y, Fiedler T, Cox M, Stamm WE. Randomized, placebo-controlled phase 2 trial of a Lactobacillus crispatus probiotic given intravaginally for prevention of recurrent urinary tract infection. Clin Infect Dis. 2011;52(10):1212-1217. DOI: 10.1093/cid/cir183Stapleton AE, Au-Yeung M, Hooton TM, Fredricks DN, Roberts PL, Czaja CA, Yarova-Yarovaya Y, Fiedler T, Cox M, Stamm WE. Randomized, placebo-controlled phase 2 trial of a Lactobacillus crispatus probiotic given intravaginally for prevention of recurrent urinary tract infection. Clin Infect Dis. 2011;52(10):1212-1217. DOI: 10.1093/cid/cir183Darouiche RO, Thornby JI, Cerra-Stewart C, Donovan WH, Hull RA. Bacterial interference for prevention of urinary tract infection: a prospective, randomized, placebo-controlled, double-blind pilot trial. Clin Infect Dis. 2005;41(10):1531-1534. DOI: 10.1086/497272Darouiche RO, Thornby JI, Cerra-Stewart C, Donovan WH, Hull RA. Bacterial interference for prevention of urinary tract infection: a prospective, randomized, placebo-controlled, double-blind pilot trial. Clin Infect Dis. 2005;41(10):1531-1534. DOI: 10.1086/497272Geldart K, Borrero J, Kaznessis YN. Chloride-Inducible Expression Vector for Delivery of Antimicrobial Peptides Targeting Antibiotic-Resistant Enterococcus faecium. Appl Environ Microbiol. 2015;81(11):3889-3897. DOI: 10.1128/AEM.00227-15Geldart K, Borrero J, Kaznessis YN. Chloride-Inducible Expression Vector for Delivery of Antimicrobial Peptides Targeting Antibiotic-Resistant Enterococcus faecium. Appl Environ Microbiol. 2015;81(11):3889-3897. DOI: 10.1128/AEM.00227-15Hwang IY, Tan MH, Koh E, Ho CL, Poh CL, Chang MW. Reprogramming microbes to be pathogen-seeking killers. ACS Synth Biol. 2014;3(4):228- 237. DOI: 10.1021/sb400077jHwang IY, Tan MH, Koh E, Ho CL, Poh CL, Chang MW. Reprogramming microbes to be pathogen-seeking killers. ACS Synth Biol. 2014;3(4):228- 237. DOI: 10.1021/sb400077jLee SJ, Lee JW. Probiotics prophylaxis in infants with primary vesicoureteral reflux. Pediatr Nephrol. 2015;30(4):609-613. DOI: 10.1007/s00467-014-2988-zLee SJ, Lee JW. Probiotics prophylaxis in infants with primary vesicoureteral reflux. Pediatr Nephrol. 2015;30(4):609-613. DOI: 10.1007/s00467-014-2988-zLangermann S, Palaszynski S, Barnhart M, Auguste G, Pinkner JS, Burlein J, Barren P, Koenig S, Leath S, Jones CH, Hultgren SJ. Prevention of mucosal Escherichia coli infection by FimH-adhesin-based systemic vaccination. Science. 1997;276(5312):607-611. DOI: 10.1126/science.276.5312.607Langermann S, Palaszynski S, Barnhart M, Auguste G, Pinkner JS, Burlein J, Barren P, Koenig S, Leath S, Jones CH, Hultgren SJ. Prevention of mucosal Escherichia coli infection by FimH-adhesin-based systemic vaccination. Science. 1997;276(5312):607-611. DOI: 10.1126/science.276.5312.607

The authors declare that there are no conflicts of interest present.